The companion animal health industry continues to experience significant growth as pet ownership rises, veterinary medicine advances, and owners increasingly seek innovative treatment options for their animals. Alongside this growth, sponsors developing pharmaceuticals, biologics, diagnostics, and other veterinary health products are navigating a rapidly evolving research environment.
As expectations for data quality, regulatory rigor, and scientific innovation continue to increase, understanding the trends shaping companion animal clinical research can help sponsors make more informed development decisions and better position their programs for success.
Increased Investment in Companion Animal Therapeutics
The companion animal market has evolved dramatically over the past decade. Pets are increasingly viewed as family members, leading to higher spending on preventive care, diagnostics, specialty treatments, and chronic disease management.
This shift has fueled investment in new therapeutic approaches targeting conditions such as osteoarthritis, dermatological disorders, oncology indications, metabolic diseases, and immune-mediated conditions. As development pipelines expand, sponsors are seeking research partners capable of generating reliable data that support critical decision-making throughout development.
Expanding Therapeutic Approaches Are Increasing Study Complexity
The veterinary therapeutic pipeline encompasses a broad range of modalities, from small molecules and peptides to biologics, monoclonal antibodies, vaccines, and other emerging approaches. As companion animal drug development continues to evolve, each modality brings its own bioanalytical considerations across different species, matrices, and study objectives.
Small- and large-molecule programs may require complementary analytical strategies, including quantitative LC-MS/MS, ligand-binding assays, hybrid LC-MS/MS, immunogenicity testing, and other specialized approaches. Each modality presents unique considerations for study design, sample analysis, pharmacokinetic evaluation, biomarker assessment, and data interpretation.
Rather than relying on a one-size-fits-all development strategy, sponsors increasingly seek research partners with expertise across multiple analytical platforms who can adapt to the specific needs of each program. The ability to support both small molecule and large molecule development has become an important advantage as pipelines continue to expand and diversify.
Pharmacokinetics and Pharmacodynamics Are Becoming More Integrated
Understanding what happens to a drug after administration remains fundamental to animal drug development, but pharmacokinetic data alone may not provide the complete picture.
Increasingly, sponsors are considering pharmacokinetics alongside pharmacodynamic endpoints and biomarkers to better understand exposure, biological activity, and response. Depending on the program, this can involve measuring drug concentrations, target engagement, pathway activity, or changes in disease-associated biomarkers.
This integrated approach helps connect:
Dose → Exposure → Biological Effect → Health Outcome
The analytical strategy supporting a study therefore needs to be designed around the questions the development program is trying to answer, rather than treating each assay as an isolated measurement.
Biomarkers Are Playing a Larger Role in Companion Animal Health Studies
Biomarker testing is becoming an increasingly important component of companion animal drug development.
Biomarkers can provide information about disease biology, treatment response, pharmacodynamic activity, or potential mechanisms of action. They may also help sponsors evaluate whether a therapeutic is producing the intended biological effect.
For companion animal health studies, biomarker analysis can provide additional context around traditional endpoints and help sponsors understand biological changes that may not be apparent from clinical observations or drug concentration data alone.
This creates opportunities for more data-rich studies, particularly as analytical technologies make it possible to measure multiple biological signals from relatively small sample volumes.ange.
Advanced Therapeutics Are Increasing the Need for Immunogenicity Testing
As more biologic and protein-based therapies enter animal drug development, understanding the immune response to a therapeutic becomes increasingly important.
Anti-drug antibody (ADA) and neutralizing antibody (NAb) assays can help characterize immunogenicity and its potential relationship to exposure, pharmacodynamics, safety, or efficacy. These assessments can be particularly important when evaluating biologics across different animal species.
Species-specific considerations also matter. Reagents, matrices, endogenous components, and immune responses can vary substantially between dogs, cats, horses, and other animals.
For sponsors developing biologics for companion animals, immunogenicity strategies therefore need to account for both the therapeutic and the species in which it is being evaluated.
Species and Matrix Considerations Are Central to Bioanalytical Method Development
A bioanalytical method that performs well in one species or matrix does not automatically translate to another. Companion animal health studies can involve serum, plasma, whole blood, urine, tissue, or other biological matrices. Differences in matrix composition, endogenous analytes, sample volume, and species biology can affect assay performance.
This makes species- and matrix-specific method development an important consideration when planning veterinary bioanalysis.
For sponsors, the practical question is often not simply:
Can this analyte be measured?
The more important question is:
Can it be measured reliably at the expected concentrations, in the species and biological matrix generated by the study?
Addressing this question early can help ensure that assay sensitivity, matrix selection, sample collection and handling, validation strategy, and study objectives are aligned before samples are generated.
Molecular and Cellular Endpoints Are Expanding the Analytical Toolkit
Companion animal health studies are also incorporating more molecular and cellular measurements. Depending on the therapeutic and disease area, studies may involve molecular assays such as qPCR or digital PCR, flow cytometry, immune cell characterization, or other cellular and molecular endpoints.
These approaches can provide information that is difficult to capture through conventional concentration measurements alone. For example, flow cytometry can help characterize changes in immune cell populations, while molecular assays can provide information about nucleic acid targets or biological responses.
As veterinary therapeutics become more targeted, these types of measurements can help create a more complete picture of how a treatment interacts with disease biology.
Data Quality and Regulatory Considerations Remain Essential
Generating data is only part of the equation. The data also needs to be appropriately characterized, documented, and presented for their intended purpose.
Regulatory expectations for animal drug development span multiple areas, including target animal safety, effectiveness, study protocol development, technical section and final study report content, and data submission. Importantly, the applicable expectations can differ depending on the purpose of the study and the data being generated. CVM guidance addresses not only study design and reporting, but also data quality, integrity, and traceability.
For sponsors, this reinforces the importance of considering the regulatory purpose of analytical data from the beginning of a program. Bioanalytical methods, sample handling, documentation, data quality, and reporting should all align with the broader development strategy.
Demand for Flexible Development Partners Is Growing
Companion animal development programs vary significantly in size, scope, therapeutic modality, and stage of development. Sponsors often require support that can scale from early feasibility studies through later-stage clinical programs while maintaining consistency in data quality, scientific oversight, and project execution.
At the same time, development timelines are becoming increasingly compressed, placing greater emphasis on efficient study management and informed decision-making. As a result, many organizations are seeking partners that combine deep scientific expertise with the flexibility to support a wide range of program needs.
Access to integrated bioanalytical capabilities, including support for small molecule and large molecule therapeutics, pharmacokinetic evaluations, biomarker testing, immunogenicity assessments, assay development, and sample management, can help streamline development activities and reduce operational complexity throughout a program’s lifecycle.
By establishing the right partnerships early, sponsors can benefit from improved communication, proactive problem-solving, and greater efficiency as their companion animal programs advance from one development milestone to the next.
What Do These Trends Mean for Companion Animal Health Studies?
The direction is clear: companion animal health studies are becoming more analytical, more targeted, and more closely connected to the broader principles of modern drug development.
The growing use of biologics and novel modalities is increasing demand for advanced bioanalysis. Biomarkers and pharmacodynamic measurements are helping researchers look beyond drug concentration alone. Immunogenicity testing is becoming increasingly relevant for biologic programs. Molecular and cellular assays are expanding the types of biological information available from animal health studies.
For sponsors, these trends make bioanalytical strategy an increasingly important part of companion animal health studies. A well-designed analytical program can help connect study design with meaningful biological and health outcomes while generating data that can support decisions throughout development.
About KCAS Bio
KCAS Bio supports companion animal health programs with bioanalytical expertise spanning both small molecule and large molecule development. From assay development and validation through sample analysis and data delivery, KCAS Bio provides the scientific support sponsors need across a wide range of veterinary therapeutic programs. Capabilities include pharmacokinetic (PK) testing, biomarker testing, immunogenicity assessments, flow cytometry, molecular biology, sample management, and other bioanalytical services designed to generate high-quality data that support informed development decisions.
Frequently Asked Questions
What are companion animal health studies?
Companion animal health studies involve the systematic evaluation of therapeutics, biologics, vaccines, diagnostics, or other interventions in animals such as dogs, cats, and horses. Studies may evaluate safety, effectiveness, pharmacokinetics, pharmacodynamics, biomarkers, immune responses, or other biological and health-related endpoints.
What bioanalytical services are used in companion animal drug development?
Common bioanalytical services include LC-MS/MS, hybrid LC-MS/MS, ligand-binding assays, PK and PD assays, immunogenicity testing, biomarker analysis, flow cytometry, molecular assays, dose formulation analysis, and sample management. The appropriate combination depends on the therapeutic modality, species, study design, and development objectives.
Are bioanalytical assays for companion animals different from human assays?
They can be. Assay performance can be influenced by species, matrix, endogenous components, available reagents, sample volume, and other biological factors. Methods may therefore require species- and matrix-specific development, optimization, or validation.
What types of companion animals can be included in health studies?
Dogs and cats are common companion animal populations, but studies may also involve horses and other animals depending on the therapeutic, disease, and intended population.
How are biomarkers used in companion animal health studies?
Biomarkers can provide information about disease biology, treatment response, pharmacodynamic activity, or mechanism of action. They can complement traditional clinical and pharmacokinetic endpoints and provide additional insight into how a therapeutic is affecting biological processes.
To learn more about our animal health expertise and how we can support your studies, fill out the form below to speak with a scientist.